CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue	$ 117	$ 0
Operating expenses:
Research and development	14,336	22,320
General and administrative	4,009	3,327
Total operating expenses	18,345	25,647
Loss from operations	(18,228)	(25,647)
Other income (expense):
Gain/(loss) from remeasurement of development derivative liability	7,233	(1,426)
Interest income	3	2
Interest expense	(148)	(285)
Foreign exchange loss	(1)	(2)
Total other income (expense)	7,087	(1,711)
Net loss	$ (11,141)	$ (27,358)
Net loss per common share, basic (in usd per share)	$ (0.23)	$ (0.87)
Net loss per common share, diluted (in usd per share)	$ (0.23)	$ (0.87)
Weighted average common shares outstanding, basic (in shares)	48,635,034	31,282,662
Weighted average common shares outstanding, diluted (in shares)	48,635,034	31,282,662
Sublicense revenue
Revenue	$ 117	$ 0